Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 2/20 | 0.47 |
| ▸ | ADCY5 | O95622 | 14/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19730183 | 0.88 | AHCY (0.47) | AHCYADCY5CHKACYP2C9IDO1 | |
| SCHEMBL19730182 | 0.83 | AHCY (0.40) | AHCYCHKA | |
| SCHEMBL19714922 | 0.82 | CHKA (0.52) | AHCYADCY5CHKA | |
| SCHEMBL19714906 | 0.81 | ADCY5 (0.60) | AHCYADCY5CHKA | |
| SCHEMBL19714902 | 0.77 | ADCY5 (0.67) | AHCYADCY5 | |
| SCHEMBL19714894 | 0.74 | AHCY (0.51) | AHCYADCY5CHKA | |
| SCHEMBL19714933 | 0.69 | CHKA (0.50) | AHCYADCY5CHKA | |
| SCHEMBL19714932 | 0.69 | CHKA (0.50) | AHCYADCY5CHKA | |
| SCHEMBL19714887 | 0.67 | ADCY5 (0.43) | AHCYADCY5CHKA | |
| SCHEMBL19714944 | 0.67 | CHKA (0.45) | AHCYCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | AHCY 672/4885ADCY5 3/4885CHKA 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.